Aurobindo Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Aurobindo Pharma Ltd reported a 1.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 5.3%.
• Its expenses for the quarter were up by 3.3% QoQ and 7.4% YoY.
• The net profit decreased 19.0% QoQ and increased 2.0% YoY.
• The earnings per share (EPS) of Aurobindo Pharma Ltd stood at 15.86 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aurobindo Pharma Ltd is a leading pharmaceutical company based in India, primarily engaged in manufacturing and marketing a wide range of generic pharmaceuticals and active pharmaceutical ingredients. The company serves a broad array of therapeutic areas, including antibiotics, antiretrovirals, cardiovascular products, and central nervous system treatments. As of the latest data, any recent major developments specific to Aurobindo Pharma Ltd are not available. The company operates within the pharmaceutical industry, which is characterized by stringent regulatory requirements and ongoing research and development efforts to innovate new drugs and formulations.

Revenue

In the fourth quarter of the fiscal year 2026, Aurobindo Pharma Ltd reported a total income of ₹8970.38 crores. This represents a 1.5% increase compared to the previous quarter (Q3FY26) where the total income was ₹8833.54 crores. On a year-over-year basis, the total income grew by 5.3% from ₹8516.93 crores in Q4FY25. The steady increase in total income over both the quarterly and annual periods reflects the company's revenue growth trajectory during this time frame.

Profitability

Aurobindo Pharma Ltd's profit before tax for Q4FY26 was ₹1293.04 crores, marking a decrease of 3.4% from ₹1338.15 crores in Q3FY26. Year-over-year, there was a decrease of 5.4% from ₹1367.28 crores in Q4FY25. Following the tax deduction of ₹369.77 crores in Q4FY26, which decreased by 13.8% from the previous quarter and 14.5% from the same quarter last year, the profit after tax was recorded at ₹920.84 crores. This result is a decrease of 19.0% from the previous quarter's ₹1137.53 crores but an increase of 2.0% from the ₹902.83 crores reported in Q4FY25. Earnings per share for Q4FY26 were ₹15.86, showcasing a marginal increase of 1.2% QoQ and a 1.9% increase YoY, indicating slight growth in shareholder value.

Operating Metrics

During the fourth quarter of FY26, total expenses were reported at ₹7677.34 crores, reflecting an increase of 3.3% from the previous quarter's ₹7430.06 crores. When compared to the same quarter in the previous year, total expenses rose by 7.4% from ₹7149.65 crores in Q4FY25. These figures highlight changes in the company's operational spending over both the quarterly and yearly periods. Specific operating ratios such as P/E ratio, debt-to-equity ratio, and current ratio are not provided in the available data, thus preventing a detailed analysis of operational efficiency and financial stability for this period based on the given information.